A mouse model of oral-esophageal carcinogenesis

Onkologie

Volumn 28, Issue 1, 2005, Pages

  Opitz, Oliver G ^a   Quante, Michael ^a   Von Werder, Alexander ^a   Heeg, Steffen ^a   Blum, Hubert E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cell cycle; Esophageal cancer; Mouse model; Oncogene; Tumor suppressor gene

Indexed keywords

CYCLIN D1; NITROSAMINE; PROTEIN P53; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CARCINOGENESIS; CONTROLLED STUDY; CROSS BREEDING; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; ESOPHAGUS CARCINOMA; GENE TARGETING; MOUSE; MOUTH CARCINOMA; MOUTH CAVITY; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; ZINC DEFICIENCY;

EID: 12544256400     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082039     Document Type: Article

References (40)

1. Patel V, Leethanakul C, Gutkind JS: New approaches to the understanding of the molecular basis of oral cancer. Crit Rev Oral Biol Med 2001;12:55-63.
2. Yang CS: Research on esophageal cancer in China: A review. Cancer Res 1980;40(8 Pt 1):2633-2644.
3. van Rensburg SJ: Epidemiologic and dietary evidence for a specific nutritional predisposition to esophageal cancer. J Natl Cancer Inst 1981;67:243-251.
4. Lu SH, Montesano R, Zhang MS, Feng L, Luo FJ, Chui SX, Umbenhauer D, Saffhill R, Rajewsky MF: Relevance of N-nitrosamines to esophageal cancer in China. J Cell Physiol 986;4 (Suppl 1):51-58.
5. Mandard AM, Hainaut P, Hollstein M: Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 2000;462:335-342.
6. Nakagawa H, Zukerberg L, Togawa K, Meltzer SJ, Nishihara T, Rustgi AK: Human cyclin D1 oncogene and esophageal squamous cell carcinoma. Cancer 1995;76:541-549.
7. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J: Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995;55:949-956.
8. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ, Sutherland RL: Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
9. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Yamamoto M, Inoue M, Yano M, Monden M: Cyclin D1 overexpression in esophageal dysplasia: A possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000;16:261-266.
10. Bradley G, Irish J, MacMillan C, Mancer K, Witterick I, Hartwick W, Gullane P, Kamel-Reid S, Benchimol S: Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma. Oncogene 2001;20:654-658.
11. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP, et al.: p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092-6097.
12. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
13. Silberman S, Shklar G: The effect of a carcinogen (Dmba) Applied to the hamster's buccal pouch in combination with croton oil. Oral Surg Oral Med Oral Pathol 1963;16:1344-1355.
14. Salley JJ: Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res 1954;33:253-262.
15. Siglin JC, Khare L, Stoner GD: Evaluation of dose and treatment duration on the esophageal tumorigenicity of N-nitrosomethylbenzylamine in rats. Carcinogenesis 1995;16:259-265.
16. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ: Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004;10(1 Pt 1):301-313.
17. Nakagawa H, Wang TC, Zukerberg L, Odze R, Togawa K, May GH, Wilson J, Rustgi AK: The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 1997;14:1185-1190.
18. Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, Kopelovich L, Nakagawa H, Rustgi AK: A mouse model of human oral-esophageal cancer. J Clin Invest 2002;110:761-769.
19. Mueller A, Odze R, Jenkins TD, Shahsesfaei A, Nakagawa H, Inomoto T, Rustgi AK: A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res 1997;57:5542-5549.
20. Fong LY, Mancini R, Nakagawa H, Rustgi AK, Huebner K: Combined cyclin D1 overexpression and zinc deficiency disrupts cell cycle and accelerates mouse forestomach carcinogenesis. Cancer Res 2003;63:4244-4252.
21. Jenkins TD, Mueller A, Odze R, Shahsafaei A, Zukerberg LR, Kent R, Stoner GD, Rustgi AK: Cyclin D1 overexpression combined with N- nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epithelium. Oncogene 1999;18:59-66.
22. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ: Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990;61:1315-1327.
23. Nakagawa H, Inomoto T, Rustgi AK: A CACCC box-like cis-regulatory element of the Epstein-Barr virus ED-L2 promoter interacts with a novel transcriptional factor in tissue-specific squamous epithelia. J Biol Chem 1997;272:16688-16699.
24. Jenkins TD, Opitz OG, Okano J, Rustgi AK: Trans-activation of the human keratin 4 and Epstein-Barr virus ED-L2 promoters by gut-enriched Kruppel-like factor. J Biol Chem 1998;273:10747-10754.
25. Magee PN: The experimental basis for the role of nitroso compounds in human cancer. Cancer Surv 1989;8:207-239.
26. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
27. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
28. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. Embo J 1994;13:2124-2130.
29. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T: Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. Embo J 1994;13:3487-3495.
30. Robles AI, Larcher F, Whalin RB, Murillas R, Richie E, Gimenez-Conti IB, Jorcano JL, Conti CJ: Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci U S A 1996;93:7634-7638.
31. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-671.
32. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-630.
33. Rodriguez-Puebla ML, Robles AI, Conti CJ: ras activity and cyclin D1 expression: An essential mechanism of mouse skin tumor development. Mol Carcinog 1999;24:1-6.
34. Suliman Y, Opitz OG, Avadhani A, Burns TC, El-Deiry W, Wong DT, Rustgi AK: p63 expression is associated with p53 loss in oral-esophageal epithelia of p53-deficient mice. Cancer Res 2001;61:6467-6473.
35. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA: Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645.
36. Artandi SE, DePinho RA: A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000;10:39-46.
37. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA: p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
38. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA: Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. Embo J 1998;17:4657-4667.
39. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-180.
40. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ: Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 2001;15:2934-2939.